Dr. Reddy's Laboratories shares in focus as company sees double-digit sales growth for FY26
In a recent update, the company's Chief Financial Officer stated that Dr. Reddy's is aiming for double-digit sales growth and a robust 25% EBITDA margin for the current financial year.
Dr. Reddy's Laboratories shares traded in a narrow range today. The stock opened at ₹1,298.10, slightly lower than its previous close of ₹1,299.80. During the session, it touched an intraday low of ₹1,277.70 and a high of ₹1,298.10. Over the past 52 weeks, the stock has seen a low of ₹1,020.00 and a high of ₹1,421.49.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
'India is selling Russian oil for big profits': Trump vows major hike in tariffs on Indian imports
In a blistering post on Truth Social, U.S. President Donald J. Trump slammed India for allegedly reselling Russian oil at a profit and ignoring the humanitarian crisis caused by Russia's invasion of Ukraine. He announced his intention to 'substantially raise' tariffs on Indian goods entering the U.S. and impose additional penalties tied to India's continued trade ties with Russia. 'India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits. They don't care how many people in Ukraine are being killed by the Russian War Machine,' Trump wrote. India now faces the prospect of a double blow from the Trump administration: a blanket 25% tariff on all U.S.-bound goods and a separate penalty for its oil and defence procurements from Russia. Trump's remarks have reignited concerns over India's growing reliance on Russian crude, which has skyrocketed from just 0.2% of imports before the Ukraine war to 35–40% today. According to Kpler data, India's Russian crude imports stood at only 68,000 barrels per day (bpd) in January 2022. That figure surged to a peak of 2.15 million bpd in May 2023. Even today, Russia remains India's largest oil supplier with an average of 1.78 million bpd—far ahead of Iraq (900,000 bpd) and Saudi Arabia (702,000 bpd). India's shift toward Russian oil began after Western nations imposed sanctions on Moscow in response to its military operations in Ukraine. Russia offered steep discounts—up to $40 per barrel below the Brent benchmark—which incentivized Indian refiners to ramp up purchases. The Trump administration has long viewed India's ongoing oil trade with Russia as a geopolitical irritant. With Trump's fresh warning and the threat of economic penalties looming, India's energy strategy and global trade dynamics could face significant disruption. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
2 hours ago
- Business Upturn
Aurobindo Pharma board declares interim dividend of Rs 4 per share for FY26
Aurobindo Pharma has announced a significant interim dividend of 400%, translating to ₹4.00 per equity share of face value ₹1 each. The decision was approved during the Board of Directors meeting held on August 4, 2025. The company has fixed August 8, 2025, as the record date to determine shareholders eligible for the dividend. Payment is scheduled to be made on or before August 21, 2025. In the exchange filings, the company shared, 'The Board of Directors of the Company at its meeting held today, August 4, 2025, has approved the payment of interim dividend of 400% i.e. Rs.4.00 (Rupee Four only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has fixed August 8, 2025, as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before August 21, 2025.' The board meeting, which began at 4:30 p.m., concluded at 5:50 p.m. This interim payout underscores Aurobindo Pharma's strong financial position and shareholder-focused approach. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
4 hours ago
- Yahoo
IDEXX Laboratories Raises Full-Year Outlook Following Second-Quarter Beat
IDEXX Laboratories (IDXX) lifted its full-year outlook on Monday as the animal diagnostics and healt
